

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 23, 2022

Leo Li
Chief Financial Officer
Burning Rock Biotech Limited
No.5 Xingdao Ring Road North, International Bio Island
Guangzhou, Guangdong
People's Republic of China

Re: Burning Rock Biotech Limited Form 20-F for the fiscal year ended December 31, 2021 Filed April 29, 2022 File No. 001-39316

Dear Mr. Li:

We have limited our review of your filing to the financial statements and related disclosures and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Form 20-F for the fiscal year ended December 31, 2021

Item 5. Operating and Financial Review and Prospects, page 95

Results of Operations, page 108

Year Ended December 31, 2021 Compared to Year Ended December 31, 2020, page 109

1. We note from page F-41 that your CODM assesses the performance of the operating segments based on "the measures of revenues, cost of revenue and gross profit by central laboratory business, in-hospital business and pharma research and development services." Please provide a more robust analysis of gross profit by segment for the periods presented as required by Item 303(b)(2)(ii) of Regulation S-K, especially considering that, for 2021 for example, gross profit increased 16.0% while gross margin decreased 1.3%.

Leo Li Burning Rock Biotech Limited August 23, 2022 Page 2

## 3 Segment Reporting, page F-41

2. We note the amounts shown in parentheses as revenue from services attributable to the inhospital business/segment for each of the three periods presented. Please clarify what these parenthetical amounts represent, e.g., an expense instead of revenue. Explain how, if at all, net recognition of these services as described on page F-30 has resulted in these negative amounts.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Jenn Do at (202) 551-3743 or Daniel Gordon at (202) 551-3486 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences